Form 4: Fractyl Health GC Receives Significant Stock Option Grant

Fractyl Health's General Counsel, Sarah Toomey, was granted 743,913 stock options with an exercise price of $2.24, vesting over three years.

Summary

• Sarah Toomey, General Counsel and an Officer of FRACTYL HEALTH, INC. (GUTS), was granted 743,913 stock options.
• The transaction date for this grant was December 15, 2025.
• The exercise price for these stock options is $2.24 per share.
• The options vest in equal installments on each of the first three anniversaries of the grant date.
• Vesting is contingent upon Ms. Toomey's continued employment through each vesting date.
• The stock options have an expiration date of December 14, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key officer is generally a positive event, aligning management incentives with shareholder interests. It reflects standard compensation practices and a commitment to retaining talent, though it does not directly impact immediate financial performance.

Positives

• The grant of stock options to a key officer like the General Counsel aligns management's financial interests with those of shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice to attract and retain executive talent in the biotechnology and healthcare sectors.

Negatives

• The stock options do not provide immediate cash value to the recipient and are subject to vesting conditions.
• The issuance of additional stock options could lead to potential future dilution for existing shareholders if exercised.

Risks

• The stock option vests and becomes exercisable only if the Reporting Person continues in employment through each vesting date, posing a risk to the recipient if employment ceases.

Future Outlook

The grant of stock options provides a long-term incentive for the General Counsel, aligning her future performance and strategic decisions with the company's growth and shareholder value creation over the next decade, subject to continued employment.

Industry Context

Equity compensation, particularly through stock option grants, is a prevalent and standard practice in the biotechnology and healthcare industries. It serves as a critical tool for attracting, retaining, and motivating key executives and employees, linking their financial success directly to the company's long-term stock performance and strategic achievements. This grant is consistent with typical executive compensation structures in the sector.

Comparison to Industry Standards

• The grant of stock options to a General Counsel is a common form of executive compensation across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule over three years is a standard practice designed to encourage long-term commitment and performance from executives, comparable to similar grants at companies like Moderna, BioNTech, or other emerging biotech firms.

Stakeholder Impact

• Shareholders: The grant aligns the General Counsel's interests with shareholder value creation, potentially leading to better long-term performance. However, it also introduces potential future dilution.
• Employees: This grant reinforces the company's compensation strategy, potentially boosting morale and retention among other key personnel.

Next Steps

• The stock options will vest in equal installments on the first, second, and third anniversaries of the grant date (December 15, 2025), subject to continued employment.

Key Dates

Keywords

Fractyl Health, GUTS, Stock Options, Insider Transaction, SEC Form 4, Equity Compensation, General Counsel, Officer Grant, Vesting Schedule